NAD+

Key Research Papers and Clinical Trials

Current research on NAD+ spans multiple therapeutic areas, though much of the evidence comes from preclinical studies and small clinical trials.

Neurological and Aging Research

Recent research has focused heavily on NAD+'s role in neurodegeneration and aging. Several 2026 review papers examine NAD+ metabolism in the context of Alzheimer's disease, exploring connections between bioenergetic impairment, tau protein modifications, and metabolic dysfunction in brain cells. These papers discuss theoretical mechanisms linking NAD+-dependent processes to neuronal energy networks, though they appear to be review articles rather than original experimental studies.

The sirtuin network, which depends on NAD+ as a cofactor, has been identified as a key connection between NAD+ metabolism, mitochondrial function, and metabolic balance. Research has also explored NAD+-related pathways in other age-related conditions, with one study examining ergothioneine's effects on circadian rhythms and another reviewing connections between virtual environments and NAD+ in healthy aging contexts.

Clinical Trial Evidence

The clinical trial landscape for NAD+ research shows mixed progress:

• Heart Failure: A completed Phase 1/2 trial (NCT03423342) investigated nicotinamide riboside, an NAD+ precursor, in patients with systolic heart failure. Results from this study have not been detailed in the provided evidence.

• Exercise and Supplementation: One completed trial (NCT04907110) examined NAD+ precursor supplementation combined with exercise, though specific outcomes are not available in the current evidence.

• Parkinson's Disease: An ongoing Phase 2 trial (NCT06162013) called the NADAPT Study is currently recruiting participants to test NAD+ replenishment therapy for atypical Parkinsonism. This randomized, double-blind trial represents one of the more advanced clinical investigations of NAD+ therapy.

Research Limitations

The evidence base shows significant gaps. Many of the recent papers appear to be reviews or mechanistic studies rather than controlled clinical trials. Sample sizes and specific study designs for the completed trials are not provided in the available evidence. The field appears to be in early stages, with more theoretical and preclinical work than robust human clinical data.

This synthesis is based on limited evidence summaries. Individuals considering NAD+ supplementation should consult healthcare providers for personalized medical advice.